EX-99.1 2 ex-99d1.htm EX-99.1 ardx_Ex99_1

Exhibit 99.1

Picture 1

Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights

     Company is poised for two Phase 3 readouts in 2H 2019 for tenapanor in hyperphosphatemia

FREMONT, Calif., March 6, 2019 -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2018.

“Over the last year, we made significant progress towards developing our lead product candidate, tenapanor, and executing on our plan to provide patients with this first-ever, non-binder treatment option for the treatment of hyperphosphatemia for patients on dialysis,” said Mike Raab, president and chief executive officer of Ardelyx. “We enter 2019 well-positioned with two years of cash on hand to deliver on our strategic goals to report results from two Phase 3 clinical trials during the second half of the year and to prepare for commercialization of our novel therapy.”

Key Accomplishments in 2018

·

Initiated the PHREEDOM clinical trial, the company’s second Phase 3 clinical trial of tenapanor for hyperphosphatemia in patients with end-stage renal disease who are on dialysis. Topline results from this trial are expected in the fourth quarter of 2019.

·

Initiated the Phase 3 AMPLIFY clinical trial, designed to evaluate expanded use of tenapanor as an adjunctive therapy to phosphate binders. Results from the AMPLIFY clinical trial are currently expected in the second half of 2019.

·

Reported the unique mechanism of action for tenapanor to inhibit paracellular phosphate absorption in Science and Translational Medicine.  

·

Submitted and received acceptance of the filing of a New Drug Application for U.S. marketing authorization of tenapanor for patients with IBS-C. The target action date under the Prescription Drug User Fee Act (PDUFA) is September 12, 2019.

·

Raised approximately $100 million through equity and debt financing to support further development and commercial launch preparation for tenapanor for the treatment of hyperphosphatemia.

·

Received a $5 million milestone payment in February 2019 from the company’s collaboration partner, Kyowa Hakko Kirin, for the initiation of a Phase 2 clinical study of tenapanor for hyperphosphatemia patients on dialysis in Japan.

Full Year 2018 Financial Results

·

Cash Position: As of December 31, 2018, Ardelyx had total capital resources including cash, cash equivalents and short-term investments of $168.1 million compared to total capital resources including cash, cash equivalents and short-term investments of $134.0 million as of December 31, 2017.

·

Revenue and Cost of Revenue: Total revenues were $2.6 million in the year ended December 31, 2018 related to the company’s ex-U.S. collaboration partnerships, and cost of revenues was $0.5 million related to payments due to AstraZeneca in accordance with the company’s termination agreement entered into with AstraZeneca in June 2015.

·

R&D Expenses: Research and development expenses were $69.4 million for the year ended December 31, 2018, a decrease of $6.1 million, or 8%, compared to $75.5 million for the year ended December 31, 2017. The decrease consisted of a $1.1 million decrease in external program costs primarily due to


 

discontinuation of the RDX7675 program and the reduction of activities associated with the RDX8940 program that was partially offset by an increase in expense related to the company’s tenapanor programs. There was a $5.0 million decrease in internal program costs primarily due to a decrease in personnel costs, including stock-based compensation costs as a result of a reduction in force during the third quarter of 2017, and a related decrease in research and development activities.

·

G&A Expenses: General and administrative expenses were $23.7 million for the year ended December 31, 2018, an increase of $0.5 million, or 2%, compared to $23.2 million for the year ended December 31, 2017. The increase was primarily due to an increase in professional services and stock-based compensation expense, partially offset by a reduction in personnel costs due to reduction in force during the third quarter of 2017.

·

Net Loss: Net loss for the year ended December 31, 2018, was $91.3 million compared to a net loss of $64.3 million for the year ended December 31, 2017.

Financial Guidance

Ardelyx maintains its expectation that its cash, cash equivalents and short-term investments will be sufficient to fund the company’s operations until at least early 2021 based on its current operating plans.

About Ardelyx, Inc.

Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing first-in-class medicines. Ardelyx's cardiorenal pipeline includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease (ESRD) who are on dialysis, and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx has completed Phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C) and submitted a new drug application, or NDA, to the U.S. Food and Drug Administration, or FDA, for the treatment of patients with IBS-C which has been granted a target action date under the Prescription Drug User Fee Act (PDUFA) of September 12, 2019. To efficiently bring its treatments to market, Ardelyx is pursuing strategic collaborations for tenapanor for IBS-C and hyperphosphatemia in certain territories. Ardelyx has established agreements with Kyowa Hakko Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada. For more information, please visit http://www.ardelyx.com/ and connect with us on Twitter @Ardelyx.

 

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including the potential for Ardelyx’s product candidates in treating the diseases and conditions for which they are being developed, the potential for the use of tenapanor as monotherapy and in combination with phosphate binders as adjunctive therapy for the treatment of hyperphosphatemia, Ardelyx’s expected timing for receipt of data from its ongoing Phase 3 clinical trials of tenapanor for the treatment of hyperphosphatemia in ESRD patients, and Ardelyx’s  expectations regarding the exhaustion of its current capital resources. Such forward-looking statements involve substantial risks and uncertainties that could cause the development of Ardelyx’s product candidates or Ardelyx’s future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical development process, the uncertainties associated with the regulatory approval process; and the uncertainties in the drug commercialization process. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx’s 

2


 

business in general, please refer to Ardelyx’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 6, 2019, and its future current and periodic reports to be filed with the Securities and Exchange Commission.

 

Investor and Media Contact:

Kimia Keshtbod 

510-745-1751

kkeshtbod@ardelyx.com

 

Sylvia Wheeler

Wheelhouse Life Science Advisors

swheeler@wheelhouselsa.com

 

Alex Santos

Wheelhouse Life Science Advisors

asantos@wheelhouselsa.com

 

3


 

Ardelyx, Inc.

Consolidated Condensed Balance Sheets

(In thousands)

 

 

 

 

 

 

 

 

 

 

December 31,

 

December 31,

 

 

 

2018

 

2017

 

 

    

(Unaudited)

    

(1)

 

Assets

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

78,768 

 

$

75,383 

 

Short-term investments

 

 

89,321 

 

 

58,593 

 

Accounts receivable

 

 

85 

 

 

10,796 

 

Unbilled license revenue

 

 

5,000 

 

 

— 

 

Property and equipment, net

 

 

5,611 

 

 

8,032 

 

Prepaid and other assets

 

 

4,547 

 

 

5,099 

 

Total Assets

 

$

183,332 

 

$

157,903 

 

 

 

 

 

 

 

 

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

Accounts payable and other current liabilities

 

$

16,728 

 

$

17,871 

 

Uncharged license fees

 

 

1,000 

 

 

— 

 

Loan payable, long term

 

 

49,209 

 

 

— 

 

Other long-term liabilities

 

 

582 

 

 

720 

 

Stockholders’ equity

 

 

115,813 

 

 

139,312 

 

Total liabilities and stockholders’ equity

 

$

183,332 

 

$

157,903 

 


(1)

Derived from the audited financial statements included on Form 10-K for the year ended December 31, 2017.

Ardelyx, Inc.

Consolidated Statements of Operations

(In thousands, except share and per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended
December 31,

 

Twelve Months Ended
December 31,

 

 

    

2018

    

2017

    

2018

    

2017

 

 

 

(Unaudited)

 

(Unaudited)

 

(Unaudited)

 

(1)

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

Licensing revenue

 

$

— 

 

$

42,000 

 

$

2,320 

 

$

42,000 

 

Other revenue

 

 

85 

 

 

— 

 

 

287 

 

 

— 

 

Total revenues

 

 

85 

 

 

42,000 

 

 

2,607 

 

 

42,000 

 

Cost of revenue

 

 

— 

 

 

8,400 

 

 

466 

 

 

8,400 

 

Gross Profit

 

 

85 

 

 

33,600 

 

 

2,141 

 

 

33,600 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

22,036 

 

$

17,159 

 

$

69,373 

 

$

75,484 

 

General and administrative

 

 

5,425 

 

 

5,479 

 

 

23,715 

 

 

23,231 

 

Total operating expenses

 

 

27,461 

 

 

22,638 

 

 

93,088 

 

 

98,715 

 

(Loss) income from operations

 

 

(27,376)

 

 

10,962 

 

 

(90,947)

 

 

(65,115)

 

Interest expense

 

 

(1,438)

 

 

— 

 

 

(3,534)

 

 

— 

 

Other income

 

 

950 

 

 

331 

 

 

3,187 

 

 

1,955 

 

Benefit from (provision for) income taxes

 

 

 

 

(1,179)

 

 

(4)

 

 

(1,179)

 

Net (loss) income

 

$

(27,862)

 

$

10,114 

 

$

(91,298)

 

$

(64,339)

 

Net (loss) income per common share, basic

 

$

(0.45)

 

$

0.21 

 

$

(1.62)

 

$

(1.36)

 

Shares used in computing net (loss) income per share, basic

 

 

62,108,906 

 

 

47,528,183 

 

 

56,219,919 

 

 

47,435,331 

 

Net (loss) income per common share, diluted

 

$

(0.45)

 

$

0.21 

 

$

(1.62)

 

$

(1.36)

 

Shares used in computing net (loss) income per share, diluted

 

 

62,108,906 

 

 

48,724,123 

 

 

56,219,919 

 

 

47,435,331 

 


(1)

Derived from the audited financial statements included on Form 10-K for the year ended December 31, 2017.

###

4